Recombinant Staphylococcus aureus Adenylosuccinate synthetase (purA)

What is the functional role of adenylosuccinate synthetase (PurA) in S. aureus metabolism?

PurA (adenylosuccinate synthetase) catalyzes a critical step in the purine biosynthesis pathway in S. aureus. Specifically, it converts IMP (inosine monophosphate) to adenylosuccinate, which is subsequently converted to AMP (adenosine monophosphate) by adenylosuccinate lyase (PurB) . This enzymatic reaction represents a pivotal junction in nucleotide metabolism, as it channels purine synthesis toward adenine nucleotides. The reaction requires GTP as an energy source and aspartate as a nitrogen donor, making PurA dependent on both purine and amino acid metabolism. In S. aureus, this enzyme is crucial for de novo purine biosynthesis, especially in environments where purine scavenging is limited, such as human blood .

How does PurA contribute to S. aureus pathogenesis?

PurA plays an essential role in S. aureus pathogenesis by enabling bacterial growth in nutrient-limited host environments. Experimental evidence demonstrates that purA mutants exhibit significantly attenuated virulence in infection models . In a zebrafish embryo infection model, purA mutants showed markedly reduced pathogenicity compared to wild-type strains, confirming this enzyme's importance for in vivo growth and virulence . This requirement indicates that S. aureus encounters purine-limited conditions during infection, necessitating de novo synthesis rather than relying solely on salvage pathways. Additionally, the growth defects observed with purA mutants on human blood agar further underscores its role in enabling successful human infection .

Why is PurA specifically required for S. aureus growth in human blood?

PurA is specifically required for S. aureus growth in human blood because this environment appears to be limiting in purines accessible to the bacterium. Analysis of purA mutants demonstrated reduced growth specifically on human blood and bovine serum agar plates while showing normal growth on sheep blood containing a richer nutrient base . This selective growth defect indicates that human blood lacks sufficient free purines for S. aureus to scavenge, forcing reliance on de novo synthesis. The specificity of this requirement highlights PurA as a potential target for antimicrobial development, as drugs inhibiting this enzyme might selectively impair S. aureus growth during bloodstream infections without affecting commensal bacteria in other tissue environments.

What structural features characterize S. aureus PurA and how do they relate to function?

The structural features of S. aureus PurA include binding domains for its substrates (IMP, GTP, and aspartate) and active site residues that coordinate catalysis. While the search results don't provide the specific crystal structure of S. aureus PurA, related orthologous enzymes such as adenylosuccinate lyase (PurB) have been crystallized and characterized . By analogy, PurA likely functions as a homodimer with each monomer containing nucleotide binding domains and catalytic regions. To determine the definitive structure, researchers should employ X-ray crystallography or cryo-electron microscopy, focusing particularly on co-crystallization with substrates or substrate analogs to elucidate the binding mechanisms and catalytic sites that could inform inhibitor design.

How does purA gene regulation occur in S. aureus under different growth conditions?

The regulation of purA gene expression in S. aureus involves multiple mechanisms responding to environmental conditions. Transcriptome analysis revealed that the eukaryotic-like serine/threonine protein kinase PknB has a strong regulatory impact on genes involved in purine biosynthesis, including purA . Under purine-limited conditions, purA expression is likely upregulated to meet cellular demands for adenine nucleotides. Additionally, mutations in the transcriptional repressor of purine biosynthesis, purR, have been shown to enhance the pathogenic potential of S. aureus, suggesting that derepression of the purine biosynthetic pathway can influence virulence . To study purA regulation experimentally, researchers should employ quantitative PCR to measure transcript levels and reporter gene fusions to monitor promoter activity under varying nutrient conditions and during infection.

What post-translational modifications affect S. aureus PurA activity?

Phosphorylation represents a key post-translational modification affecting S. aureus PurA activity. Research has demonstrated that PurA can be phosphorylated by the serine/threonine protein kinase PknB, resulting in a significant 1.8-fold decrease in enzymatic activity compared to the unphosphorylated form . This regulatory mechanism allows S. aureus to modulate purine biosynthesis in response to environmental conditions and stress. To study this modification, researchers should employ in vitro phosphorylation assays using purified PknB and PurA, followed by mass spectrometry to identify specific phosphorylation sites. Site-directed mutagenesis of these sites (converting serine/threonine to alanine or to phosphomimetic residues like aspartate) can further elucidate the functional consequences of this modification.

What expression systems yield optimal production of functional recombinant S. aureus PurA?

For optimal recombinant production of S. aureus PurA, E. coli-based expression systems typically offer the highest yield and simplicity. The methodological approach should involve:

• Vector selection: pET vectors with T7 promoters provide high-level expression for cytoplasmic proteins like PurA.

• Host strain optimization: BL21(DE3) derivatives, particularly Rosetta strains that supply rare codons, can improve expression of S. aureus proteins.

• Expression conditions: Lower induction temperatures (16-25°C) often improve protein solubility by slowing folding kinetics.

• Fusion tags: N-terminal His6 or MBP tags facilitate purification while potentially enhancing solubility.

Expression trials should systematically vary IPTG concentration (0.1-1.0 mM), induction temperature, and duration to identify conditions that maximize soluble protein yield. For challenging cases, cell-free expression systems represent an alternative approach that can overcome toxicity issues sometimes encountered with metabolic enzymes.

What purification strategies maximize recovery of active S. aureus PurA?

A multi-step purification strategy is recommended to obtain high-purity, active S. aureus PurA:

• Affinity chromatography: Immobilized metal affinity chromatography (IMAC) using Ni-NTA resin for His-tagged PurA provides effective initial capture.

• Ion exchange chromatography: Anion exchange (typically Q-Sepharose) at pH 8.0 further resolves PurA from contaminants with different charge properties.

• Size exclusion chromatography: Final polishing step separates different oligomeric states and removes aggregates.

Throughout purification, supplement buffers with glycerol (10%) and reducing agents (1-5 mM DTT) to maintain enzyme stability. Activity assays monitoring the conversion of IMP to adenylosuccinate should be performed after each step to track functional protein recovery.

How can researchers overcome solubility and stability challenges with recombinant S. aureus PurA?

Addressing solubility and stability challenges with recombinant S. aureus PurA requires a systematic approach:

• Buffer optimization: Screen various buffer conditions (pH 6.5-8.5), salt concentrations (50-500 mM NaCl), and additives (glycerol, arginine, trehalose) using differential scanning fluorimetry (thermal shift assays) to identify stabilizing conditions.

• Codon optimization: Synthesize the purA gene with codons optimized for the expression host to enhance translation efficiency.

• Co-expression strategies: Co-express PurA with molecular chaperones (GroEL/ES, DnaK/J/GrpE) to facilitate proper folding.

• Fusion partners: MBP, SUMO, or thioredoxin fusion tags can dramatically improve solubility of difficult proteins.

• Storage conditions: Evaluate protein stability in various storage conditions, including:

  • Buffer additives (glycerol 10-20%, reducing agents)

  • Flash freezing versus slow freezing

  • Lyophilization potential

  • Temperature (-80°C, -20°C, 4°C)

Long-term stability should be monitored through periodic activity assays after storage at different temperatures and through multiple freeze-thaw cycles.

What methods effectively measure S. aureus PurA enzymatic activity?

Several complementary assays can be employed to measure S. aureus PurA enzymatic activity:

• Spectrophotometric continuous assay: This approach monitors the increase in absorbance at 280 nm as IMP is converted to adenylosuccinate. While straightforward, this method has lower sensitivity due to the modest difference in extinction coefficients between substrate and product.

• Coupled enzyme assay: PurA activity can be coupled to NADH oxidation through auxiliary enzymes that utilize reaction products, allowing monitoring at 340 nm. This provides enhanced sensitivity but requires careful controls to ensure coupling enzymes aren't rate-limiting.

• HPLC-based endpoint assay: This more labor-intensive approach directly quantifies substrate consumption and product formation using reverse-phase HPLC, offering high specificity and the ability to detect partial reactions or side-products.

• Malachite green phosphate detection: This assay measures inorganic phosphate released during the reaction, providing a colorimetric readout suitable for high-throughput screening.

For kinetic characterization, researchers should employ at least two orthogonal methods to confirm results and rule out assay artifacts.

What are the optimal reaction conditions and kinetic parameters for S. aureus PurA?

The optimal reaction conditions for S. aureus PurA activity include:

• Buffer: 50 mM HEPES or Tris-HCl, pH 7.5-8.0

• Temperature: 30-37°C (physiological temperature for S. aureus)

• Divalent cations: 5-10 mM Mg²⁺ (essential cofactor)

• Substrates: IMP (0.1-1 mM), GTP (0.1-1 mM), and aspartate (1-10 mM)

• Ionic strength: 50-150 mM KCl or NaCl

To determine kinetic parameters, researchers should perform steady-state kinetic analysis by varying the concentration of one substrate while maintaining others at saturating levels. This approach yields the following typical parameters (which should be experimentally determined for S. aureus PurA):

Additionally, product inhibition studies with AMP and adenylosuccinate should be conducted to fully characterize the enzyme's regulatory properties, as these may differ between S. aureus and other bacterial species.

How does phosphorylation specifically alter the enzymatic parameters of S. aureus PurA?

Phosphorylation by PknB reduces S. aureus PurA enzymatic activity by approximately 1.8-fold compared to the unphosphorylated form . To characterize this regulation mechanistically, researchers should:

• Prepare homogeneously phosphorylated PurA using purified PknB and ATP, confirming modification by mass spectrometry and Phos-tag gel electrophoresis.

• Compare kinetic parameters between unmodified and phosphorylated PurA, determining changes in:

  • Substrate affinity (Km for IMP, GTP, and aspartate)

  • Catalytic efficiency (kcat/Km)

  • Maximum reaction rate (Vmax)

  • Potential alterations in allosteric regulation

• Use phosphomimetic mutants (Ser/Thr to Asp/Glu) and phosphoablative mutants (Ser/Thr to Ala) at identified phosphorylation sites to dissect the contribution of individual modifications.

• Perform isothermal titration calorimetry to directly measure changes in substrate binding energetics upon phosphorylation.

These analyses would reveal whether phosphorylation primarily affects substrate binding, catalytic rate, or both, providing insights into how S. aureus modulates purine biosynthesis in response to environmental conditions.

What genetic approaches are most effective for studying purA function in S. aureus?

Multiple genetic approaches can be employed to study purA function in S. aureus:

• Conditional expression systems: Since purA is essential under many conditions, inducible promoters (tetracycline-responsive, IPTG-inducible) allow controlled expression to study partial loss-of-function phenotypes.

• CRISPR interference (CRISPRi): This approach enables tunable repression of purA expression without modifying the coding sequence. Design guide RNAs targeting the promoter or non-template strand of purA and use a catalytically dead Cas9 (dCas9) to achieve repression.

• Allelic replacement: Generate point mutations in purA to study specific residues involved in catalysis or regulation, using temperature-sensitive plasmids or CRISPR-Cas9 systems optimized for S. aureus.

• Fluorescent protein fusions: Create transcriptional or translational fusions to monitor purA expression and PurA localization under different conditions.

• Transposon mutagenesis: Screen for suppressor mutations that rescue purA deficiency to identify metabolic bypass pathways.

Each approach should include appropriate controls and complementation studies to confirm phenotypic specificity.

How can researchers differentiate between direct and indirect effects of purA mutations on S. aureus phenotypes?

Differentiating direct from indirect effects of purA mutations requires multiple complementary approaches:

• Metabolic profiling: Use targeted metabolomics to measure purine nucleotide pools (ATP, ADP, AMP) and related metabolites in wild-type and purA mutant strains. Direct effects should show immediate changes in adenylate pools.

• Complementation analysis: Express wild-type purA from an inducible promoter in the mutant background, titrating expression levels to determine the minimum required for phenotype rescue.

• Temporal analysis: Use time-course experiments after purA inactivation to distinguish primary (rapid) from secondary (delayed) effects on physiology and gene expression.

• External nucleotide supplementation: Attempt to rescue purA mutant phenotypes with adenine or adenosine supplementation. Phenotypes corrected by supplementation are likely direct consequences of purine limitation.

• Transcriptome and proteome analysis: Compare gene expression profiles between wild-type and purA mutants to identify compensatory responses versus direct consequences of adenylate deficiency.

These methodological approaches collectively provide evidence for causality versus association in observed phenotypes.

What infection models best demonstrate the contribution of PurA to S. aureus pathogenesis?

Several infection models effectively demonstrate PurA's contribution to S. aureus pathogenesis:

• Zebrafish embryo model: This system has already proven valuable for demonstrating the role of purA in pathogenesis . Advantages include optical transparency, ease of genetic manipulation, and conservation of innate immune responses.

• Murine bacteremia model: Intravenous infection of mice with wild-type S. aureus versus purA conditional mutants can reveal the importance of purine biosynthesis during bloodstream infection, tracking bacterial loads in organs and survival rates.

• Human whole blood ex vivo infection: This approach directly tests the requirement for PurA in human blood, allowing assessment of bacterial survival and growth while enabling manipulation of blood components to identify specific factors influencing purine availability.

• Tissue cage model: Subcutaneous implantation of tissue cages followed by S. aureus inoculation enables longitudinal sampling from a defined infection site, permitting assessment of purA expression and the effect of purA manipulation over time.

• Cell culture infection models: Human endothelial or epithelial cell infection models can assess whether purA is required for intracellular survival and persistence, a key feature of S. aureus pathogenesis.

What criteria establish S. aureus PurA as a viable antimicrobial target?

S. aureus PurA meets several critical criteria that establish it as a viable antimicrobial target:

• Essentiality: PurA is required for S. aureus growth in human blood and for full virulence in infection models, making it an essential virulence factor .

• Absence of bypass mechanisms: The growth defect of purA mutants on human blood indicates limited ability of S. aureus to scavenge purines from this environment, suggesting lack of effective metabolic bypass routes during infection .

• Conservation: PurA is conserved across S. aureus strains, suggesting that resistance through target alteration would likely incur significant fitness costs.

• Druggability: As an enzyme with defined substrates and products, PurA likely possesses binding pockets amenable to small molecule inhibition.

• Potential for selectivity: Differences between bacterial and human adenylosuccinate synthetases could enable development of selective inhibitors with minimal host toxicity.

Target validation should include demonstration that chemical inhibition of the enzyme attenuates bacterial virulence in infection models and assessment of resistance frequency.

What approaches can identify selective inhibitors of S. aureus PurA?

Multiple complementary approaches can identify selective inhibitors of S. aureus PurA:

• Structure-based virtual screening: Using the determined or modeled structure of S. aureus PurA, perform in silico docking of compound libraries, prioritizing molecules predicted to bind the active site or allosteric regions.

• Fragment-based screening: Use biophysical methods (thermal shift assays, surface plasmon resonance, NMR) to identify small chemical fragments that bind to PurA, which can then be elaborated into higher-affinity compounds.

• High-throughput enzymatic assays: Develop a miniaturized, plate-based assay suitable for screening large compound libraries, using the spectrophotometric or coupled methods described in section 4.1.

• Whole-cell pathway-specific screening: Screen for compounds that create a purA-deficient phenotype in wild-type S. aureus, but not in strains engineered to bypass purine biosynthesis requirements.

• Rational design based on transition state analogs: Design compounds that mimic the transition state of the PurA reaction, potentially achieving high-affinity binding.

For each approach, counter-screening against human adenylosuccinate synthetase is essential to identify compounds with selectivity for the bacterial enzyme.

How should researchers assess inhibitor specificity and potential for resistance development?

Comprehensive assessment of inhibitor specificity and resistance potential includes:

• Enzymatic specificity profile:

  • IC₅₀ determination against S. aureus PurA

  • IC₅₀ determination against human adenylosuccinate synthetase

  • Testing against related enzymes (GMP synthetase, other ATP-utilizing enzymes)

  • Mechanism of inhibition studies (competitive, noncompetitive, uncompetitive)

• Cellular specificity assessment:

  • MIC determination against S. aureus clinical isolates

  • Cytotoxicity testing in human cell lines (HepG2, primary hepatocytes)

  • Activity testing in the presence of serum and under various nutrient conditions

  • Confirmation of on-target activity through metabolomics (adenylate pool measurement)

• Resistance evaluation:

  • Frequency of resistance determination

  • Whole-genome sequencing of resistant mutants

  • Characterization of resistant enzyme variants

  • Fitness cost assessment of resistance mutations

  • Multi-passage exposure studies to assess stepwise resistance development

• In vivo efficacy and safety:

  • PK/PD relationship determination in animal infection models

  • Toxicity assessment in multiple species

  • Efficacy in immunocompromised models to assess dependence on immune system

This methodical approach ensures development of inhibitors with appropriate selectivity and reduced resistance potential.

How does PurA activity integrate with broader S. aureus metabolic networks?

PurA activity integrates with broader S. aureus metabolic networks through multiple connections:

• Energy metabolism: PurA utilizes GTP, linking purine biosynthesis to energy metabolism and GTP-producing pathways like the TCA cycle.

• Amino acid metabolism: The requirement for aspartate connects PurA activity to amino acid metabolism and nitrogen assimilation pathways.

• Nucleotide balance: PurA influences the ratio of adenine to guanine nucleotides, affecting numerous cellular processes from DNA replication to protein synthesis.

• Cell wall biosynthesis: The relationship between purine metabolism and cell wall activity is indicated by the finding that PknB (which phosphorylates PurA) regulates both purine biosynthesis and cell wall metabolism genes .

To study these integrations experimentally, researchers should employ:

• Metabolic flux analysis using ¹³C-labeled precursors

• Network analysis of transcriptomic responses to purA manipulation

• Synthetic lethal screening to identify genes with functional relationships to purA

• Metabolomics profiling under purA limitation or inhibition

These approaches would reveal how S. aureus coordinates purine biosynthesis with other metabolic processes during infection and stress.

What is the relationship between PurA activity and stress responses in S. aureus?

The relationship between PurA activity and stress responses in S. aureus involves several interconnected mechanisms:

• Phosphorylation-mediated regulation: PurA is phosphorylated by PknB, a kinase that responds to cell wall stress and other environmental conditions . This suggests that stress conditions trigger modulation of purine biosynthesis through post-translational modification.

• Transcriptional regulation: Mutations in purR, the transcriptional repressor of purine biosynthesis, enhance the pathogenic potential of S. aureus, indicating that altered purine metabolism regulation occurs under stress conditions .

• Metabolic adaptation: Under nutrient limitation or antibiotic stress, reorganization of metabolic fluxes likely affects purine biosynthesis, as demonstrated by the sensitivity of a pknB deletion strain to the cell wall-active antibiotic tunicamycin .

To investigate these relationships experimentally, researchers should measure purA expression, PurA phosphorylation status, and adenylate pools under various stress conditions, including:

• Oxidative stress (H₂O₂ exposure)

• Antibiotic treatment (sub-MIC concentrations)

• Nutrient limitation (carbon, nitrogen, phosphate)

• Host defense mechanisms (antimicrobial peptides, phagocytosis)

These studies would elucidate how S. aureus modulates purine metabolism as part of its stress response repertoire.

How do changes in purine biosynthesis affect S. aureus virulence gene expression?

Changes in purine biosynthesis can significantly impact S. aureus virulence gene expression through multiple mechanisms:

• Direct regulatory effects: Adenine nucleotides (ATP, cAMP) serve as cofactors or allosteric regulators for transcription factors controlling virulence genes.

• Energy-dependent regulation: Altered ATP levels affect energy-dependent processes like DNA supercoiling and protein phosphorylation that influence virulence gene expression.

• Stringent response: Purine limitation triggers the stringent response through (p)ppGpp synthesis, globally reprogramming transcription including virulence factors.

• Metabolic sensing: Transcription factors that sense metabolic state (e.g., CcpA, CodY) respond to changes in nucleotide pools, coordinating metabolism with virulence.

To investigate these connections experimentally, researchers should:

• Perform RNA-seq comparing wild-type S. aureus to strains with altered purA expression

• Analyze virulence factor production (hemolysins, adhesins) under controlled purA expression

• Measure intracellular alarmone concentrations ((p)ppGpp) in response to purine limitation

• Use chromatin immunoprecipitation sequencing (ChIP-seq) to identify transcription factor binding changes resulting from altered purine metabolism

Understanding these relationships could reveal novel approaches to attenuate virulence by modulating purine biosynthesis.

How can PurA be leveraged for vaccine development against S. aureus infections?

PurA offers several possibilities for S. aureus vaccine development:

• PurA as a vaccine antigen: While not extensively studied as a vaccine candidate, other metabolic enzymes like enolase (ENO), phosphoglycerate kinase (PGK), and elongation factor-G (EF-G) have shown promise as S. aureus vaccine antigens . Recombinant PurA could be evaluated as part of a multi-component subunit vaccine.

• PurA-deficient live attenuated vaccines: Engineered strains with regulated purA expression could serve as live attenuated vaccines, able to initiate immune responses but incapable of causing disseminated infection.

• Metabolic mimicry: Chemical inhibition of PurA during natural infection could create an "attenuated" infection state that allows development of protective immunity while limiting disease severity.

• Adjuvant development: Understanding how purine metabolites influence immune responses could inform adjuvant design for S. aureus vaccines.

Research approaches should include:

• Immunogenicity studies of recombinant PurA in mice

• Assessment of protective efficacy against multiple S. aureus strains

• Characterization of antibody and T-cell responses, particularly IL-17A production which has been associated with protection

• Evaluation of PurA in combination with other antigens to achieve synergistic protection

What emerging technologies might advance understanding of PurA function in S. aureus?

Several emerging technologies promise to advance understanding of PurA function:

• Single-cell techniques: Methods like single-cell RNA-seq and mass cytometry can reveal heterogeneity in purA expression and PurA activity within bacterial populations, potentially identifying persister subpopulations with altered metabolism.

• Genome-wide CRISPR screens: CRISPRi/CRISPRa screens can identify genes that synthetically interact with purA or compensate for purA deficiency, revealing novel metabolic relationships.

• Proximity labeling proteomics: BioID or APEX2 fusions to PurA can identify protein interaction partners under various conditions, revealing regulatory complexes and unexpected functional connections.

• Cryo-electron tomography: This technique can visualize the spatial organization of metabolic enzymes within intact S. aureus cells, potentially revealing metabolic compartmentalization.

• Time-resolved structural techniques: Methods like time-resolved crystallography and single-molecule FRET can capture PurA in different conformational states during catalysis.

• Nanobody-based sensors: Developing conformational sensors for PurA could enable real-time monitoring of enzyme activity in living cells.

These technologies would provide unprecedented insights into how PurA functions within the complex cellular environment of S. aureus during infection.

What computational approaches can predict PurA inhibitor efficacy across diverse S. aureus strains?

Advanced computational approaches for predicting PurA inhibitor efficacy include:

• Homology modeling and molecular dynamics: Generate models of PurA from diverse S. aureus strains, including clinical isolates, and use molecular dynamics simulations to identify conformational changes that might affect inhibitor binding.

• Machine learning-based prediction: Train machine learning algorithms on existing enzyme inhibition data to predict efficacy against variant PurA sequences, incorporating features like binding site conservation, physicochemical properties, and predicted binding energies.

• Quantitative structure-activity relationship (QSAR) models: Develop QSAR models that correlate inhibitor chemical structures with activity against different PurA variants.

• Network pharmacology approaches: Model the effects of PurA inhibition in the context of strain-specific metabolic networks to predict efficacy and resistance potential.

• Population genomics analysis: Analyze PurA sequence variation across S. aureus populations to identify conserved regions most suitable for targeting and predict natural polymorphisms that might confer resistance.

The implementation of these approaches requires:

• High-quality activity data against a diverse panel of S. aureus strains

• Structural information for multiple PurA variants

• Integration of genomic, transcriptomic, and metabolomic datasets

• Validation using experimental evolution and resistance selection studies

Such computational frameworks would accelerate development of broad-spectrum inhibitors effective against the diversity of S. aureus strains encountered in clinical settings.